logo
Purses made from T. rex? This company claims leather made from 66 million-year-old dinosaur DNA is coming

Purses made from T. rex? This company claims leather made from 66 million-year-old dinosaur DNA is coming

New York Post01-05-2025

About 66 million years ago, the Tyrannosaurus rex roamed around Earth terrifying nature around it.
Now, one of the largest predators ever to live on land can be your next purse.
Researchers and bioengineers are working to create the next cruelty-free and sustainable luxury handbag using lab-grown leather from fossilized T. rex remains from the prehistoric creature.
Advertisement
That's right -— in the year 2025, dinosaurs are Jurass-chic.
'We're unlocking the potential to engineer leather from prehistoric species, starting with the formidable T-Rex,' Che Connon, professor of tissue engineering at Newcastle University, said in a statement.
The first-of-its-kind approach to luxury fashion uses T. rex DNA as a groundbreaking high-quality alternative to traditional leather.
Advertisement
If successful, this would be the first-ever sample of a leather that's sourced from an extinct species — though some experts don't think it's possible.
The partnership between creative agency VML, genomic engineering leader The Organoid Company and sustainable biotechnology pioneer Lab-Grown Leather Ltd. would portray how ancient biology can create a next-generation material that will ultimately influence the future of luxury goods.
The lab-grown fossilized T. rex collagen will be used as a blueprint to manufacture a material that's structurally identical to traditional leather. It will also be biodegradable and 'innovative and ethically sound.'
Unlike naysayers, Connon said it will soon become a reality.
Advertisement
'The hard bit is making leather from cells, and we've done that,' Connon told The Post. 'The upstream bit is using existing technologies, which is why we're confident we can do this so quickly.'
6 An AI mock-up of what a handbag made from T. rex leather would look like.
VML/SWNS
The initial implementation of T. rex leather will focus on accessories with a goal to produce a flagship commercial luxury fashion item by the end of the year.
Eventually, once production gets larger, this could open the door to possibilities beyond the fashion industry, such as the automotive sector.
Advertisement
'With T-Rex leather we're harnessing the biology of the past to create the luxury materials of the future,' Bas Korsten, Global Chief Creative Officer, Innovation & CCO EMEA at VML, said in a statement.
'Part of it is the fact that it's demonstrating that you can start to create new materials that have never been formed before,' Connon said. 'So the same process could be used to create much stronger, for example, or change color or a whole host of things that are feasible but have never been seen before.'
6 T. rex leather infographic explaining how the lab-grown engineering differs from the current leather process.
VML
In order to create it, synthetic DNA will be used to engineer cells that will then be integrated into an Elemental-X product stream, utilizing a scaffold-free approach that allows the cells to merge in their own natural structure.
Connon explained that he and his team spent 15 years in university doing tissue engineering, then three to four years at the company to get to the point of making the skin and the leather.
'This project is a remarkable example of how we can harness cutting-edge genome and protein engineering to create entirely new materials,' Thomas Mitchell, CEO of The Organoid Company, commented.
'By reconstructing and optimizing ancient protein sequences, we can design T. Rex leather, a biomaterial inspired by prehistoric biology, and clone it into a custom-engineered cell line.'
According to VML, the T. rex leather is a cell-grown performance material that is more than just imitation and provides the natural durability, repairability and tactility that's already expected in high-end luxury leather goods.
Advertisement
6 The T. rex leather is a cell-grown performance material.
TeTe Song – stock.adobe.com
However, not all scientists are digging the revelations. One dinosaur expert told Live Science he thinks the claim of making T. rex leather is 'misleading' and 'what this company is doing seems to be fantasy.'
'We have NO preserved tyrannosaurid DNA (indeed, not Mesozoic dinosaur DNA sequences), so there are no T. rex genes,' Thomas Holtz, Jr., a vertebrate paleontologist at the University of Maryland, told the outlet.
DNA starts to decay as soon as an animal dies, though some fragments might remain in the environment for a few million years. The oldest preserved DNA on record is about 2 million years old, and the T. rex went extinct 66 million years ago.
Advertisement
Holtz added that paleontologists have only found T. rex collagen in bone, not skin, which is the basis for leather, and that researchers don't have access to good tyrannosaurid skin samples since it's rarely preserved in fossils.
6 The new approach to luxury fashion uses T. rex DNA as a groundbreaking high-quality alternative to traditional leather.
Boonyawadee.K – stock.adobe.com
Some experts are less skeptical, noting that while it may be possible, any chance of getting results soon isn't likely, and when they do, it'll be expensive.
The 'gimmick' is at a 'very early stage,' Tom Ellis, professor of synthetic genome engineering at Imperial College London, told NBC. 'I doubt that our knowledge of dinosaur evolution is good enough to be able to design a collagen gene specifically from T. rex.'
Advertisement
Ellis added that producing real T. rex leather is 'very far-fetched,' and the properties of any collagen results are likely to be similar to those of a cow or chicken, which means that it would look and feel the same as any other alternative leather.
Though the T. rex collagen 'gives them something that is at least unique and can justify a much higher price,' he said.
6 Professor Che Connon explained that the collagen fragments extracted is available from blood vessels or micro-vessels in bone.
Newcastle University
But Connon rebuked the notion that it's not possible, telling The Post that 'some people have got the wrong end of the stick saying, well, you can't do it. That's not true.'
Advertisement
'Some of that seems to be around, there is no T-Rex skin, but leather isn't skin. It's a component of skin,' he explained. 'So that's a bit of confusion there. The technologies there are incredible, but they are very much there. And I think the challenge is, there's a lot to bring people up to speed with.'
As he explained, the collagen fragments extracted are available from blood vessels or micro-vessels in bone, and the blood vessels have the same biological makeup as skin. 'It's the structural part of the skin, which forms leather.'
'People aren't aware of all the different technologies or aware that they exist, so putting them together is quite a bit of a mental leap for people,' Connon said. 'But rest assured, these are all things that have been proven.'
6 Eventually, this could open the door to possibilities beyond the fashion industry, such as the automotive sector.
Panupong – stock.adobe.com
The researchers also stressed the environmental and ethical consequences of the lab-grown leather as well. Since traditional leather production is a component of extensive deforestation and the tanning process often uses harmful chemicals, this new approach can not only reduce negative environmental impacts but also put an end to animal cruelty concerns.
'Dinosaurs evolved to survive in extreme environments—conditions our planet is once again beginning to face due to accelerated climate change,' the news release also explained.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nuclear fusion record smashed as German scientists take 'a significant step forward' to near-limitless clean energy
Nuclear fusion record smashed as German scientists take 'a significant step forward' to near-limitless clean energy

Yahoo

timea day ago

  • Yahoo

Nuclear fusion record smashed as German scientists take 'a significant step forward' to near-limitless clean energy

When you buy through links on our articles, Future and its syndication partners may earn a commission. A recently concluded experimental campaign at the Wendelstein 7-X stellarator at the Max Planck Institute for Plasma Physics (IPP) in Greifswald, Germany has smashed previous fusion records and set a new benchmark for reactor performances. Nuclear fusion offers a tantalizing promise of unlimited clean energy. By smashing together isotopes (or different versions) of hydrogen at incredibly high temperatures, the resulting superheated plasma of electrons and ions fuses into heavier atoms, releasing a phenomenal amount of energy in the process. However, while this fusion reaction is self-sustaining under the extraordinary temperatures and pressures within stars, recreating these conditions on Earth is a huge technical challenge — and current reactor concepts still consume more energy than they are able to produce. Stellarators are one of the most promising reactor designs, so named for their mimicry of reactions in the sun. They use powerful external magnets to control the high-energy plasma within a ring-shaped vacuum chamber and maintain a stable, high pressure. Unlike simpler tokamak reactors — which pass a high current through the plasma to generate the required magnetic field — stellarators' external magnets are better at stabilizing the plasma through the fusion reactions, a feature that will ultimately be necessary when translating the technology to commercial power plants. In the recent experiments, the W7-X stellarator outperformed previous benchmarks set by the decommissioned tokamak reactors JT60U in Japan and JET in the UK, especially over how long the plasma can be sustained. Related: Nuclear fusion could be the clean energy of the future Most notably, the international team revealed that the reactor had reached a new record high triple product — a key metric for the success of fusion power generators. The triple product is a combination of the density of particles in the plasma, the temperature required for these particles to fuse, and the energy confinement time (a measure of how well the thermal energy is held by the system). A certain minimum value called the Lawson criterion marks the point at which the reaction produces more energy than it uses and becomes self-sustaining, so a higher triple product indicates a more efficient reaction. "The new record is a tremendous achievement by the international team," said Thomas Klinger, Head of Operations at Wendelstein 7-X and Head of Stellarator Dynamics and Transport at IPP in a statement. "Elevating the triple product to tokamak levels during long plasma pulses marks another important milestone on the way toward a power-plant-capable stellarator." Key to the success of this latest milestone was the development of a new fuel pellet injector that combined continuous refueling of the reactor with pulsed heating to maintain the required plasma temperature. Over a 43-second period, 90 frozen hydrogen pellets were fired into the plasma at up to 2,600 feet (800 metres) per second, roughly the speed of a bullet. Pre-programmed pulses of powerful microwaves heated the plasma, which reached a peak temperature of 30 million degrees C, and this coordination between the microwave pulses and the pellet injection crucially extended how long the plasma could be stably maintained. RELATED STORIES —Physicists solve nuclear fusion mystery with mayonnaise —There's 90,000 tons of nuclear waste in the US. How and where is it stored? —Just a fraction of the hydrogen hidden beneath Earth's surface could power Earth for 200 years, scientists find This same campaign also increased the energy turnover of the reaction to 1.8 gigajoules over a six-minute run, smashing the reactor's previous record of 1.3 gigajoules from February 2023. Energy turnover is a combination of the heating power and plasma duration of a fusion reactor and an indication of the reactor's ability to sustain the high-energy plasma. It is therefore another crucial parameter for future power plant operation. The new value even exceeds the record achieved by the Experimental Advanced Superconducting Tokamak (EAST) in China earlier this year, further evidencing stellarators' potential. "The records of this experimental campaign are much more than mere numbers. They represent a significant step forward in validating the stellarator concept—made possible through outstanding international collaboration," summarized Robert Wolf, Head of Stellarator Heating and Optimization at IPP in statement.

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer
Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

Yahoo

time2 days ago

  • Yahoo

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

MENLO PARK, Calif., June 04, 2025--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the appointment of senior leaders to support the company as it advances its lead investigational allogeneic T-cell immunotherapy, Orca-T®, toward potential commercial launch. Steve Gavel has joined Orca Bio as Chief Commercial Officer after most recently serving as Senior Vice President, Global Cell Therapy Commercial Development at Legend Biotech. Orca Bio has also strengthened its broader commercial organization with the addition of several senior leaders with extensive cell therapy experience to oversee Market Access, Commercial Operations and Medical Affairs. In addition to these key commercial appointments, Allison Frisbee has joined Orca Bio as a Senior Vice President, Legal, following roles at Kronos Bio, Jazz Pharmaceuticals and Bristol Myers Squibb, and as outside counsel to life science companies at Orrick, Herrington and Sutcliffe. Steve Gavel - Chief Commercial Officer Gavel brings over 30 years of experience in the biotechnology and pharmaceutical sectors, with deep expertise in the commercialization of cell and gene therapies having led strategy and execution since the earliest days of the field. "We are thrilled to welcome Steve to the Orca Bio team. Steve is a cell therapy veteran with a proven track record of building and scaling organizations in preparation for commercialization," said Nate Fernhoff, Ph.D., Co-founder and Chief Executive Officer at Orca Bio. "As we prepare for the commercial launch of Orca-T, Steve brings a perfect combination of background, experience and strategic vision to lead Orca Bio into this next phase of growth and maturation." At Legend Biotech, Gavel grew and scaled its commercial organization across multiple CAR-T therapies, including leading the successful global launch of Carvykti®, a treatment for patients with relapsed or refractory multiple myeloma. There he oversaw the global commercial development efforts including launch readiness, market access and commercial operations. Prior to Legend Biotech, Gavel led U.S. commercial strategy and development at Celgene (now Bristol Myers Squibb). Before then, he held commercial roles of increasing seniority at companies including Millennium Pharmaceuticals, IMS Health, West Pharmaceutical Services and Discovery Labs. "I'm honored to join Orca Bio as it prepares to bring its groundbreaking cell therapy to patients with high-risk blood cancers, including acute myeloid leukemia and myelodysplastic syndrome," said Steve Gavel, Chief Commercial Officer at Orca Bio. "The company's pioneering team has achieved remarkable progress, and with approximately 500 patients treated on trial to date, the potential of its novel high-precision platform is already being realized. I look forward to joining the company as we work to unlock new opportunities for growth and transform the therapeutic landscape for patients with blood cancer." Allison Frisbee - Senior Vice President, Legal Frisbee joins with strong experience as a legal and operations leader in the life science industry, with a focus on translating complex legal and regulatory challenges into clear, strategic solutions. Prior to joining Orca Bio, Frisbee served as the Chief Administrative Officer at Kronos Bio, where she oversaw a broad portfolio including Legal, HR, Facilities, IT and Compliance. Before joining Kronos, she held senior legal roles at Jazz Pharmaceuticals and Bristol Myers Squibb. "I'm thrilled to join the team at Orca Bio and help continue shaping a thoughtful, values-driven legal and compliance function," said Allison Frisbee, Senior Vice President, Legal at Orca Bio. "It's a privilege to partner with teams who are not only advancing transformative therapies, but leading with a deep commitment to integrity, accountability and an unwavering commitment to doing what's right for patients." About Orca Bio Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases. The company's manufacturing platform uses single-cell precision to create proprietary, uniquely-defined products designed to replace a patient's diseased blood and immune system with a healthy one. At Orca Bio, we are on a mission to redefine what's possible for patients by transforming the field of curative allogeneic cell therapy. For more information, visit Trademarks or registered trademarks used in this press release are the property of their respective owners. View source version on Contacts Corporate CommunicationsKelsey Grossmanmedia@ Investor RelationsJoshua Murrayir@

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer
Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

Business Wire

time2 days ago

  • Business Wire

Orca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the appointment of senior leaders to support the company as it advances its lead investigational allogeneic T-cell immunotherapy, Orca-T®, toward potential commercial launch. Steve Gavel has joined Orca Bio as Chief Commercial Officer after most recently serving as Senior Vice President, Global Cell Therapy Commercial Development at Legend Biotech. Orca Bio has also strengthened its broader commercial organization with the addition of several senior leaders with extensive cell therapy experience to oversee Market Access, Commercial Operations and Medical Affairs. In addition to these key commercial appointments, Allison Frisbee has joined Orca Bio as a Senior Vice President, Legal, following roles at Kronos Bio, Jazz Pharmaceuticals and Bristol Myers Squibb, and as outside counsel to life science companies at Orrick, Herrington and Sutcliffe. Steve Gavel - Chief Commercial Officer Gavel brings over 30 years of experience in the biotechnology and pharmaceutical sectors, with deep expertise in the commercialization of cell and gene therapies having led strategy and execution since the earliest days of the field. 'We are thrilled to welcome Steve to the Orca Bio team. Steve is a cell therapy veteran with a proven track record of building and scaling organizations in preparation for commercialization,' said Nate Fernhoff, Ph.D., Co-founder and Chief Executive Officer at Orca Bio. 'As we prepare for the commercial launch of Orca-T, Steve brings a perfect combination of background, experience and strategic vision to lead Orca Bio into this next phase of growth and maturation.' At Legend Biotech, Gavel grew and scaled its commercial organization across multiple CAR-T therapies, including leading the successful global launch of Carvykti®, a treatment for patients with relapsed or refractory multiple myeloma. There he oversaw the global commercial development efforts including launch readiness, market access and commercial operations. Prior to Legend Biotech, Gavel led U.S. commercial strategy and development at Celgene (now Bristol Myers Squibb). Before then, he held commercial roles of increasing seniority at companies including Millennium Pharmaceuticals, IMS Health, West Pharmaceutical Services and Discovery Labs. 'I'm honored to join Orca Bio as it prepares to bring its groundbreaking cell therapy to patients with high-risk blood cancers, including acute myeloid leukemia and myelodysplastic syndrome,' said Steve Gavel, Chief Commercial Officer at Orca Bio. 'The company's pioneering team has achieved remarkable progress, and with approximately 500 patients treated on trial to date, the potential of its novel high-precision platform is already being realized. I look forward to joining the company as we work to unlock new opportunities for growth and transform the therapeutic landscape for patients with blood cancer.' Allison Frisbee - Senior Vice President, Legal Frisbee joins with strong experience as a legal and operations leader in the life science industry, with a focus on translating complex legal and regulatory challenges into clear, strategic solutions. Prior to joining Orca Bio, Frisbee served as the Chief Administrative Officer at Kronos Bio, where she oversaw a broad portfolio including Legal, HR, Facilities, IT and Compliance. Before joining Kronos, she held senior legal roles at Jazz Pharmaceuticals and Bristol Myers Squibb. 'I'm thrilled to join the team at Orca Bio and help continue shaping a thoughtful, values-driven legal and compliance function,' said Allison Frisbee, Senior Vice President, Legal at Orca Bio. 'It's a privilege to partner with teams who are not only advancing transformative therapies, but leading with a deep commitment to integrity, accountability and an unwavering commitment to doing what's right for patients.' About Orca Bio Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases. The company's manufacturing platform uses single-cell precision to create proprietary, uniquely-defined products designed to replace a patient's diseased blood and immune system with a healthy one. At Orca Bio, we are on a mission to redefine what's possible for patients by transforming the field of curative allogeneic cell therapy. For more information, visit Trademarks or registered trademarks used in this press release are the property of their respective owners.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store